Abstract:Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in 2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women globally. Breast cancers have been categorized into four major molecular subtypes based on the immunohistochemistry (IHC) expression of classic hormone and growth factor receptors including the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as a proliferation marker Ki-67 protein expression. Triple-negative breast cancer (TNBC), a breast cancer subtype lacking ER, PR, and HER2 expression, is associated with a high metastatic potential and poor prognosis. TNBC accounts for approximately only 15%–20% of new breast cancer diagnoses; it is responsible for most breast cancer–related deaths due to the lack of targeted treatment options for this patient population, and currently, systemic chemotherapy, radiation, and surgical excision remain the major treatment modalities for these patients with TNBC. Although breast cancer patients in general do not have a robust response to the immunotherapy, a subset of TNBC has been demonstrated to have high tumor mutation burden and high tumor-infiltrating lymphocytes, resembling the features observed on melanoma or lung cancers, which can benefit from the treatment of immune checkpoint inhibitors (ICIs). Therefore, the immunogenic nature of this aggressive disease has presented an opportunity for the development of TNBC-targeting immunotherapies. The recent US Food and Drug Administration approval of atezolizumab in combination with the chemotherapeutic agent nab-paclitaxel for the treatment of PD-L1-positive unresectable, locally advanced, or metastatic TNBC has led to a new era of immunotherapy in TNBC treatment. In addition, immunotherapy becomes an active research area, both in the cancer biology field and in the oncology field. In this review, we will extend our coverage on recent discoveries in preclinical research and early results in clinical trials from immune molecule-based therapy including cytokines, monoclonal antibodies, antibody–drug conjugates, bi-specific or tri-specific antibodies, ICIs, and neoantigen cancer vaccines; oncolytic virus-based therapies and adoptive immune cell transfer–based therapies including TIL, chimeric antigen receptor-T (CAR-T), CAR-NK, CAR-M, and T-cell receptor-T. In the end, we will list a series of the challenges and opportunities in immunotherapy prospectively and reveal novel technologies such as high-throughput single-cell sequencing and CRISPR gene editing-based screening to generate new knowledges of immunotherapy.

Nectin-4 has emerged as a compelling target for breast cancer

Targeted Therapeutic Strategies for Nectin-4 in Breast Cancer: Recent Advances and Future Prospects

Therapeutic prospects of nectin-4 in cancer: applications and value

Nectin-4: A promising prognostic marker and therapeutic target in cancer

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

Nectin-4 expression in primary breast cancer and associated clinical outcomes.

Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer

Production and characterization of single-chain variable fragment antibodies targeting the breast cancer tumor marker nectin-4

Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer

Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence

Nectin-4 is widely expressed in head and neck squamous cell carcinoma

Nectin-4 as a Predictive Marker for Poor Prognosis of Endometrial Cancer with Mismatch Repair Impairment

Abstract 1916: Discovery of a novel Nectin4 IPSC-derived cell therapy for the treatment of solid tumors

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity

Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes

LINC01572 promotes triple‐negative breast cancer progression through EIF4A3‐mediated β‐catenin mRNA nuclear exportation

Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers With68ga-N188

Targeting neuropilin-1 interactions is a promising anti-tumor strategy

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer